Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Dranitsaris

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
International Journal of Technology Assessment in Health Care|September 28, 2004
Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapyGeorge Dranitsaris, Pauline Leung
Applied Health Economics and Health Policy|October 3, 2014
Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?George Dranitsaris, George Papadopoulos
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 28, 2012
Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patientsGeorge Dranitsaris, Eleftheria Hatzimichael
Current Oncology (Toronto, Ont.)|November 10, 2022
Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021Catherine Lau, George Dranitsaris
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 30, 2014
Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time?George Dranitsaris, Mark Clemons
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 26, 2010
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysisGeorge Dranitsaris, Haytham Khoury
Applied Health Economics and Health Policy|June 30, 2009
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysisGeorge Dranitsaris, Sanjay Mehta
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 28, 2013
Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropeniaJames A Chiarotto, George Dranitsaris
Journal of Evaluation in Clinical Practice|January 22, 2014
Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and costGeorge Dranitsaris, Anne K Ellis
Breast Cancer Research and Treatment|September 14, 2014
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabineGeorge Dranitsaris, Mario E Lacouture
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
International Journal of Technology Assessment in Health Care|September 28, 2004
Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapyGeorge Dranitsaris, Pauline Leung
Applied Health Economics and Health Policy|October 3, 2014
Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?George Dranitsaris, George Papadopoulos
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 28, 2012
Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patientsGeorge Dranitsaris, Eleftheria Hatzimichael
Current Oncology (Toronto, Ont.)|November 10, 2022
Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021Catherine Lau, George Dranitsaris
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 30, 2014
Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time?George Dranitsaris, Mark Clemons
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 26, 2010
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysisGeorge Dranitsaris, Haytham Khoury
Applied Health Economics and Health Policy|June 30, 2009
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysisGeorge Dranitsaris, Sanjay Mehta
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 28, 2013
Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropeniaJames A Chiarotto, George Dranitsaris
Journal of Evaluation in Clinical Practice|January 22, 2014
Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and costGeorge Dranitsaris, Anne K Ellis
Breast Cancer Research and Treatment|September 14, 2014
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabineGeorge Dranitsaris, Mario E Lacouture
Pageof 14